Good day, ladies and gentlemen and welcome to the Repligen Corporation's Fourth Quarter Full Year 2016 Earnings Conference Call. My name is Shannon and I will be your coordinator. At this time, all participants are in a listen-only mode. Please note that there will be a question-and-answer period following the company's formal remarks. In order to accommodate all individuals who wish to ask questions, there will be a limit of three questions at a time. I would now like to turn the call over to your host for today's call, Sondra Newman, Senior Director of Investor Relations for Repligen.

Thank you and good morning. The purpose of today’s call is to report our financial results for the fourth quarter and full year 2016 to provide financial guidance for the year 2017 and to discuss recent business highlights. Joining me today are Tony Hunt, our President and CEO; and Jon Snodgres, our CFO. On this call, we will be making forward-looking statements regarding our business goals and our expectations for the financial performance of the Company. We caution you that such statements are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning these risk factors is discussed in our annual report on Form 10-K, the current report on Form 8-K which we filed today and other filings that we make with the Securities and Exchange Commission. The forward-looking statements in today's discussion reflect management's current views and may become obsolete as a result of new information, future events or otherwise. The Company doesn't obligate or commit itself to update forward-looking statements except as required by law. During this call, we will be presenting our financial results for 2016 and providing guidance for 2017 on an adjusted or non-GAAP basis. Our financial results for 2016 will be provided on both GAAP and non-GAAP basis and our financial guidance will be non-GAAP only. Reconciliation of GAAP to non-GAAP financial measures are included in our press release issued this morning which is posted to Repligen’s website as well as sec.gov. Our adjusted figures will include the following: revenue growth at constant currency; adjusted gross margin; adjusted operating income, adjusted net income, adjusted fully diluted earnings per share, EBITDA and adjusted EBITDA. While these adjusted financial measures should not be viewed as an alternative to GAAP measures, the company believes that the use of these non-GAAP measures better enables investors to benchmark Repligen’s current results against historical performance and the performance of peers and to evaluate investment opportunities. With that, I will turn the call over to Tony Hunt for a business update.

Thank you, Sondra. Good morning everybody and welcome to our year end update. Before jumping into the performance in Quarter four and full year 2016, I want to spend a few minutes covering our strategy and execution over the last few years. 2016 was a milestone year for the company, surpassing a $100 million in revenue in our fifth year as a pure play bioprocessing company having transitioned away from higher [ph] therapeutics back in 2012. Over the last five years, we’ve focused our efforts on developing and acquiring best-in-class technologies that has enabled meaningful efficiency gains in the production of Biologics. We’ve built out our infrastructure and operations, both internally and externally. We’ve invested in our people, bringing in top industry talent and a first class global commercial team. These investments have resulted in strong and consistent double digit revenue growth and multiple new product lines through internal R&D like our large scale OPUS 45, 60 and OPUS.com [ph] and single used versions of our market leading XCell ATF systems. We have also executed on three strategic acquisitions since 2014 by the strength in our direct to customer portfolio and positioned us well in the market as single used and continuous processing technologies gain further traction. All three acquisitions are a strong set with our business and we have successfully leveraged the commercial team and infrastructure to accelerate the growth in the adoption of these assets. Driven by this combination of internal innovation and acquisition, we have established the Repligen brand to represent both technology leadership and the primary customer experience in the world of higher processing. Most importantly, we have pivoted the company, saw a direct to customer product portfolio has grown over six fold and now represents approximately 50% product revenue in 2016 compared with only 20%…

Thank you, Tony and good morning everyone. Today, we are reporting our financial results for the fourth quarter and full year 2016 as well as providing our financial guidance for the year 2017. As a reminder, we will be discussing our results and projections using non-GAAP financial measures with respect to our performance. We used these non-GAAP indicators for financial and operational decision making and as a means to evaluate our performance. As we move into the financial discussion, please recall that we closed on the acquisition of TangenX on December 14 and our fourth quarter and full year 2016 non-GAAP financial statements includes approximately $120,000 of TangenX revenue recorded before the end of the year of holiday shutdown period. The acquired business incurred a small loss in the fourth quarter due to timing of the acquisition we considered diminimus through our overall results. Now moving to our fourth quarter of 2016 adjusted non-GAAP financial results. Our financial results for the fourth quarter of 2016 were highlighted by strong sales of our bioprocessing products. We are reporting total revenue of $25.6 million, an increase of 19% as reported and 21% at constant currency compared to the fourth quarter of 2015. Our gross profit for the fourth quarter was $13.4 million, an increase of $2.1 million, or 19% over the fourth quarter of 2015. Our gross margin was 52.5% for the fourth quarter of 2016 compared to 52.7% in 2015. The change in year-over-year gross margin is a result of product mix, predominately driven by strong sales of OPUS pre packed coloumns, inventory step up charges from our TangenX acquisition and from operational investments made in our facilities to support the growing demand for our products. Adjusted operating income for the fourth quarter of 2016 grew to $3.8 million, an increase…

Thank you. [Operator Instructions] Our first question is from Brandon Couillard with Jefferies. You may begin.

Thanks. Good morning. Appreciate all the detail there. Tony, just in terms of the Protein A business, is your visibility gotten better sort of over the last several weeks. Do you seeing the point of an approving forecast from GE and Millipore, your partners there. And is it fair to say that you contemplated sort of a low single-digit growth outcome for that side of the business this year?

Yes. Overall as we discussed in prior calls, the ligands business was a lumpy business in 2015 and we definitely saw inventory burn off at both our customers and their customer end users, but for sure as we moved through Q1 the forecast have strengthened and so we’re encouraged by that. And I think we’re also encouraged by the fact that the pipeline of mAbs that are up for approval is still very healthy. So, yes, I think in terms of mid single-digit growth for that overall business is what we’re anticipating.

And then, one for OPUS, you point that adding to new productions suites in the first quarter here. At some point will it become more realistic or more -- or let’s say at some point would you begin to think about shifting production capacity more into the local markets outside of the U.S. closer to customer base in Europe and Asia? And as you add additional capacity, is any additional value you can extract from perhaps allocating some of that capacity to a few of the larger customers that have platform on OPUS, those are wide adoption?

Yes. Its clearly, 2016 was a milestone year for the chromatography business and for OPUS in general. And I think our number one goal last year was to drive down lead times as the demand security went up significantly. So, when we brought on the two new suites in September that was to really drive down the lead times from where we were in mid year to where we ended up at the end of the year. Now we’re right now down into single-digit weeks [ph] as lead times for the product, so its come down pretty significantly. So adding in the two new suites that we’re doing right now is adding further capacity for us, its giving us more flexibility for those large customers that you refer to, so we would be able to use those suites in a way that we can use it for specific accounts or for opportunities that are going to crop up with very short lead times. So, it’s giving us a lot more flexibility. And for sure as we look towards the rest of this year and into 2018 our goal would be to put some production suites into Europe. Right now, I think we're doing a really good job of getting the lead times down to where they need to be. So we’re scheduled to put in those production suites by the end of the year, beginning of next year and that's kind of the plan as we start 2017. But, yes, I think that's really a quick update on that.

And this one for Jon, you spiked out the TangenX’s revenue contribution late in the fourth quarter. Give us the total revenue impact from M&A which I guess would include Atoll both in the fourth quarter, and then what you contemplated in the guide for 2017?

Sure.

And get an organic number?

Yes. We gave you the guidance for Atoll was early on the year $3 million to $3.5 million was comfortably within that range for this year and next for revenue should give you one-third of point. TangenX should have 120,000 for the year. And then we had guided separately the TangenX’s business to be between $7 million and $7.5 million for 2017. So – and we expect the OPUS PD product line from Atoll business to grow in double-digits.

Great. Thank you.

Thank you. Our next question is from Drew Jones with Stephens. You may begin.

Thanks. Good morning, guys.

Hi, Drew.

Good morning.

Just looking at the margins a little bit and understanding there are lot of moving pieces especially that pertains to OPUS. Has the incremental capacity for OPUS had an impact on margins there, or is the growth that’s not having an impact?

Yes. So it has had an impact. We’ve added basically CapEx into our facilities, so we’ve added some additional depreciation cost. We’ve added personnel as well as we’ve expanded to a second shift. And really we’re trying to stay ahead of the growth curve on OPUS. So, it's definitely the cost had some impact. The mix had some impact. Though in the fourth quarter we typically have, also as we’ve spoken about in prior years, some effect from year-end shutdown periods and that type of thing and as we go forward we’re optimistic that we can drive a little margin expansion this year and we’re guiding between 55.5% to 56 5%. And the challenge with OPUS is really, as customers account [ph] the product line having them basically first procure the resin where they get bigger discounts when we do on the resin, plus ship that resin to us and thereby improving our mix of columns versus resin mix. And so, that’s one of our key areas of improvement this year and we’re expecting to see some benefit from that.

And then, when you guys announced TangenX, you talk a little bit about the constraint being on distribution sales force, as you plugged it into your commercial organization where is the kind of easiest cross-sell, is it your OPUS customer or somewhere else?

No. It’s definitely the OPUS customer because TangenX technology, the TFF single-use product line, it’s the next step after the OPUS column, so it's a natural sort of stuff call point for our sales reps. So they can talk to their customers about OPUS and then there's a conversation that can happen around concentration of the mAb or the protein both the third column in the process. So, the good news is, as we obviously built out our commercial organization over the last three plus years, many of the people that we’ve brought on board have filtration background. So this is an easy fit for them and adds quite nicely into the portfolio. So their experience works and I think the call point works for us.

Thanks guys.

Thank you. Our next question comes from Paul Knight with Janney, You may begin.

Hi, Tony, can you talk about market uptake on the polymer version of ATF and that rollout what September occurred?

Yes. So, we launched the Single-use version of ATF. We launched the Single-use ATF 2 and ATF 6 in September, and we hit exactly what we were forecasting for the years. So we actually had very good traction in Q4, and we think that the advantage of the Single-use product is clearly around ease-of-use and ease-of-implementation, and that’s what the customers are experiencing. So again, this year we expect that we’ll continue to see good uptake in Single-use sales and obviously launching single-use ATF 10 gives us the full portfolios. So customers who are buying and implementing at two or six have a path forward to a 10 and late clinical or commercial scale processes. So, we expect obviously not a huge amount of revenue from Single-use in 2017, but clearly as we go through the next two, three, four years it's going to be one of the major drivers of growth for that product line.

And then, looking at the Atoll and TangenX acquisitions, are they able to be tucked into your existing sales force or is that why you need to add more people could you talk about the level of synergy you're getting from these acquisitions. Is it a new sales force you’re having to build kind of you talk to the possible synergy in the distribution part of the business?

Sure. Let’s start with Atoll. Clearly the Atoll which is now OPUS PD which is small-scale column fits very, very well with our overall OPUS portfolio and is a natural call point for our sales team. So, instead of talking to the, let’s say, the manufacturing organizations with the OPUS PD, our product line is ready with process development groups. And for TangenX as I said a few minutes ago, it's a natural fit with the OPUS call point as well as our sales books are talking to the exact same end user. I think the -- when we look at our overall business the addition of the sales people is really not necessarily due to the impact of Atoll or TangenX, it's just really the acceleration that we’re seeing of our direct to customer products and so as I sat down in Q4 and started to look at our - at the regions and at the territories we could see areas in North America and in Europe where we had significant amount and needed more feet [ph] on the street. So that's really the rationale around adding salespeople. The field applications folks are coming in really to have more of the technical conversations with our customers. So as our product line gets a little bit more complex and complicated. As you go from pre-packed columns to selling ATF Systems for perfusion or for hybrid perfusion processes and now talking about TFF platforms down in the purification workflow. They become a little bit more technical in terms of the conversations and require a combination of sales and field applications, people to have the right interactions with our customers. So again, I think we signal this last year that we would be adding in field applications people, and again North America and Europe is where we’re adding FAS and we’ll be adding a person into Asia as well to support the growing business there.

And then, my last question, Tony, as the Samsung and [Indiscernible] expansion, the huge expansion of what they’re doing in the Asian market. Is that good for your business or what’s the effect of what they're doing?

Yes. In general the Asian market has been -- has done very well over the last few years. Though we've gone from almost a standing start with very little revenue to now 8% to 10% of the revenues of the company are coming for Asia. So you can see the progress we've made. And I think when you look at companies like Gucci [ph] and Samsung and there are other companies over there as well that are expanding. That’s good, that’s good for bio-processing. It’s is good for Repligen especially if you have your products in their workflows.

Thank you.

Thank you. Our next question comes from Matt Tiampo with Craig-Hallum. You may begin.

Hi. I just have quick ones. Congrats on the quarter and strong first year, but what was the mix within OPUS [Indiscernible 37:14] versus resin that you are procuring yourself as you guys did in 2016.

So, Matt, it hasn’t changed that much since our Q3 call. I think back in Q3, we were – I think we signalled that it was around at 50:50 mix, and that’s where we ended for the year more or left and I would say as we go into 2017 where I expect that we’ll see a shift towards a 60:40 split, I’m not saying that that’s exactly how we’ll end up, but that’s really the direction we are going in as more large pharma and more multi column order comes through the national progression is for those customers to drop shift the resins to us and that’s definitely the trend we are seeing.

Okay, thanks very much.

[Operator Instructions] And I’m showing no further questions at this time. I’d like to turn the call back over to Tony Hunt for closing remarks.

Great. Just like to thank everybody for joining us and look forward to bringing up to speed in a few months on our Q1 results. Thank you.

Ladies and gentlemen, this concludes today’s conference. Thanks for your participation. Have a wonderful day. You may now disconnect.